<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006353</url>
  </required_header>
  <id_info>
    <org_study_id>FB-ABWT-401</org_study_id>
    <nct_id>NCT04006353</nct_id>
  </id_info>
  <brief_title>The Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 4, Single-center, Open-label, Parallel Study to Evaluate the Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to estimate the drug interaction between RIF and ABT. This will be a&#xD;
      single-center, open-label, parallel study in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to describe and compare RIF and ABT pharmacokinetics following&#xD;
      administration of 320mg ABT and 600mg RIF.12 subjects will receive 320mg ABT on Days 1、2、3、8&#xD;
      (Treatment 1). And 12 subjects will receive 600mg RIF daily for 16 days from Day 1 to 16, and&#xD;
      receive 320mg ABT on Days 7、8、9 and 14 (Treatment 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Actual">December 3, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of ABT following ABT 320mg administration with and without RIF 600mg qd</measure>
    <time_frame>Up to 17 days</time_frame>
    <description>Pharmacokinetic(PK) parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of RIF 600mg qd administration with and without ABT 320mg</measure>
    <time_frame>Up to 17 days</time_frame>
    <description>PK parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of ABT following ABT 320mg administration with and without RIF 600mg qd</measure>
    <time_frame>Up to 17 days</time_frame>
    <description>PK parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of RIF 600mg qd administration with and without ABT 320mg</measure>
    <time_frame>Up to 17 days</time_frame>
    <description>PK parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal findings for laboratory parameters</measure>
    <time_frame>Up to 17 days</time_frame>
    <description>Number of subjects with Grade 3/4 laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events.</measure>
    <time_frame>Up to 17 days</time_frame>
    <description>An adverse event is any untoward medical occurrence in a clinical study subject, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with severity of adverse events</measure>
    <time_frame>Up to 17 days</time_frame>
    <description>The Division of AIDS table for grading the severity of adult and pediatric adverse events will be used to assess severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Drug Interaction</condition>
  <arm_group>
    <arm_group_label>Group 1: ABT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 320 mg ABT on Day 1, 2, 3, and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: ABT+RIF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg Rifampicin once daily from Day 1 to 16. Intravenous infusion of 320 mg ABT on Day 7, 8, 9 and 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT</intervention_name>
    <description>320 mg, Intravenous infusion</description>
    <arm_group_label>Group 1: ABT</arm_group_label>
    <arm_group_label>Group 2: ABT+RIF</arm_group_label>
    <other_name>albuvirtide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIF</intervention_name>
    <description>600mg q.d.</description>
    <arm_group_label>Group 2: ABT+RIF</arm_group_label>
    <other_name>rifampicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, age between 18 and 65 years；&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including physical examination, laboratory tests, Chest X-ray, abdominal&#xD;
             B-ultrasound and ECG; No serious liver and kidney dysfunction, normal albumin value,&#xD;
             and other indicators are in the normal range；&#xD;
&#xD;
          -  Subjects weighing ≥50 kg and their BMI within the range 18.5-27.0 kg/m^2 (inclusive)；&#xD;
&#xD;
          -  Agrees not to consume alcohol during the study；&#xD;
&#xD;
          -  Both male and female subjects and their partners of childbearing potential agree to&#xD;
             use contraception during the study；&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening visit prior to receiving the first dose of study drug；&#xD;
&#xD;
          -  ALT、AST、ALP and TBIL≤1×ULN；&#xD;
&#xD;
          -  Willing and able to participate in all aspects of the study, including use of&#xD;
             intravenous medication, completion of subjective evaluations, attendance at scheduled&#xD;
             clinic visits, and compliance with all protocol requirements as evidenced by providing&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive anti-HIV-1 antibody result；&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen result；&#xD;
&#xD;
          -  A Positive Hepatitis C antibody result；&#xD;
&#xD;
          -  Syphilis infection as manifest by positive RPR；&#xD;
&#xD;
          -  History of tuberculosis (TB) or lung disease；&#xD;
&#xD;
          -  Currently active severe chronic diseases, metabolic diseases (such as diabetes),&#xD;
             cardiovascular diseases, neurological and psychiatric diseases；&#xD;
&#xD;
          -  Any known allergy or antibodies to the study drug or rifampicin；&#xD;
&#xD;
          -  Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant&#xD;
             during the study；&#xD;
&#xD;
          -  Active alcohol or drug abuse；&#xD;
&#xD;
          -  Participation in an experimental drug trial(s) within 30 days or 5 half-lives of the&#xD;
             Screening Visit；&#xD;
&#xD;
          -  Currently active or chronic gastrointestinal dysfunction, or liver and kidney function&#xD;
             disorders, would affect the absorption, metabolism, and/or excretion of the study&#xD;
             drug. Subjects with a history of cholecystectomy, pepticulcer, inflammatory bowel&#xD;
             disease or pancreatitis should be excluded；&#xD;
&#xD;
          -  Use other prescription or over-the-counter medications, including vitamins, herbal&#xD;
             medicines, or dietary supplements, 7 days prior to dosing or 5 half-life, unless the&#xD;
             investigator believes that the drug will not interfere with the study procedure or&#xD;
             compromise the safety of the subject；&#xD;
&#xD;
          -  Any other clinical condition that, in the Investigator's judgment, would potentially&#xD;
             compromise study compliance or the ability to evaluate safety/efficacy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongzhou Lu, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Public Health Clinical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

